CT Lottery: Pair of $50,000 prizes claimed, other winners Wednesday, April 2
Check out the winners for Wednesday, April 2, according to the CT Lottery:
$50,000 winner in New Haven, CT
Game: $50,000 Cashword
Retailer: Washington Ave Deli in New Haven, CT
$50,000 winner in Cheshire, CT
Game: CA$H PLU$
Retailer: Sunshine Convenience Store in Cheshire, CT
$20,000 winner in New Haven, CT
Game: 20X Cash 9th Edition
Retailer: Cumberland Farms in Old Saybrook, CT
$10,000 winner in Beacon Falls, CT
Game: $100,000 CA$HWORD
Retailer: New Dp Mart in Naugatuck, CT
$10,000 winner in West Haven, CT
Game: 10X™ Cash 17th Edition
Retailer: Krauszer's Food Store in West Haven, CT
Family-owned CT hardware store for sale after 100 years. 'It's home,' longtime customers say
$10,000 winner in Bridgeport, CT
Game: 10X™ Cash 17th Edition
Retailer: Milford Quick Mart in Milford, CT
$10,000 winner in Newington, CT
Game: 10X™ Cash 17th Edition
Retailer: Mobil On The Run in Hartford, CT
$10,000 winner in New Haven, CT
Game: 20X Cash 9th Edition
Retailer: Connecticut Lottery Corp in Hartford, CT
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
an hour ago
- Indianapolis Star
Arrive AI Celebrates Nasdaq Debut by Ringing Opening Bell with Early Supporters, Pioneering the Future of Autonomous Delivery
INDIANAPOLIS, INDIANA / ACCESS Newswire Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by Arrive Points™ – is set to mark a pivotal moment in its journey by ringing Nasdaq's opening bell on July 3, 2025. More than 300 of the company's foundational investors, alongside team members, will join the celebration, highlighting the incredible support that fueled Arrive AI's ascent to the public market. 'This isn't just about ringing a bell; it's a testament to the vision and unwavering belief of our early investors who stood with us every step of the way,' said Arrive CEO Dan O'Toole. 'This landmark achievement is for everyone who joined our journey and made this moment possible. We are the real 'we the people' story!' Arrive AI officially began publicly trading on May 15, 2025. The company is rapidly transforming the autonomous delivery landscape with its Arrive Points, intelligent, networked smart mailboxes that serve as universal access points for both traditional and autonomous deliveries. This proprietary network offers an ever-growing suite of services, ranging from real-time data tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. The system seamlessly integrates with smart home devices such as doorbells, lighting and security systems, to streamline and secure the entire last-mile delivery experience. O'Toole's journey from designing the prototype Arrive Point on a napkin to ringing the Nasdaq bell began in 2014 when he sought U.S. Patent Office protection for his smart mailbox design. In doing so, he edged out Amazon by four days and other industry leaders by weeks. He secured that foundational patent in 2017 and has continued to refine the product and has also developed an AI-driven network and platform. Arrive AI now holds eight patents for its proprietary technology. Six additional patents are pending. Arrive AI has a total of 58 patents pending for its ALM solution filed across 22 countries and has secured several trademarks. See details at The latest patent highlights the Arrive Points' cutting-edge capabilities, including: Climate control: Ensuring the integrity of sensitive deliveries, Battery charging and exchange station: Supporting the evolving needs of autonomous vehicles, Advanced safety features: A collector for identifying explosive materials and anthrax, and ultraviolet and ozone applicators to eradicate disease, viruses and harmful materials, and Comprehensive monitoring: Weather monitoring; vehicle and package tracking; facial recognition camera and software for both humans and pets; local two-way speakers; and integrated flood light and strobe LED lighting. Arrive AI is actively collaborating with leaders in the healthcare industry where efficiency, accuracy and security are paramount for deliveries. O'Toole emphasizes the platform's vast potential for data tracking and other services, solidifying its position as a universal access point for the entire autonomous logistics industry. -30- About Arrive AI: Arrive AI's patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at Media contact: Cheryl Reed at media@ Investor Relations Contact: Alliance Advisors IR at Cautionary Note Regarding Forward Looking Statements This news release and statements of Arrive AI's management in connection with this news release or related events contain or may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as 'expects', 'anticipates', 'intends', 'plans', 'believes', 'potential', 'will', 'should', 'could', 'would' ,'optimistic' or 'may' and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI's public filings for more complete information, including the risk factors that may affect future results, which are available for review at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
Business Wire
an hour ago
- Business Wire
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
SYDNEY--(BUSINESS WIRE)--As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Business Wire
an hour ago
- Business Wire
One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row
DALLAS--(BUSINESS WIRE)--Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World 1 by Euromonitor International for the third consecutive year. Mary Kay products are sold by best-in-class Independent Beauty Consultants who provide personalized service to customers in person and online at and on social and digital media channels. Share Euromonitor International is the foremost provider of global business intelligence, market analysis, and consumer insights with over 50 years of conducting market research across more than 100 countries. "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay,' said Ryan Rogers, Chief Executive Officer of Mary Kay. 'This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." In addition to the global recognition, Mary Kay has been named: #1 Brand of Facial Make-Up in Latin America,* #1 Brand of Lip Products in Latin America,* #1 Brand of Color Cosmetics in Mexico,* #1 Brand of Skincare and Color Cosmetics in Mexico.* Sarah Boumphrey, Global Research Director at Euromonitor International, stated, 'Our awards reflect the highest standard of excellence in the industries we track, and beauty and direct selling are no exception. Honorees are recognized through a rigorous, data-driven evaluation process that draws on independent research, global market analysis, and deep category expertise. Euromonitor is proud to collaborate with leading companies, like Mary Kay, and this accomplishment signifies their commitment to performance and quality in a highly competitive landscape." With presence in over 40 markets and millions of Independent Beauty Consultants around the world, Mary Kay continues to set the standard for beauty that empowers and delivers. Several fan-favorite products contribute to Mary Kay's #1 status, including the iconic TimeWise ® skincare line, the dermatologist validated Clinical Solutions ® skincare line, the Mary Kay ® Oil-Free Eye Makeup Remover beloved by influencers and celebrities, the Mary Kay ® Ultimate Mascara™, the Mary Kay Unlimited ® Lip Gloss, and the Mary Kay ® Waterproof Eyeliner, to name a few. In 2024 alone, Mary Kay garnered 65 beauty awards around the world. In addition to the Euromonitor International #1 recognition, Mary Kay recently ranked #11 in the Women's Wear Daily Beauty Inc.'s 2024 Top 100 Beauty Companies. Mary Kay products are sold by best-in-class Independent Beauty Consultants who provide personalized service to customers in person and online at and on social and digital media channels. The Euromonitor award reinforces Mary Kay as one of the world's best loved brands with a business model and corporate mission focused on empowering women, transforming lives, and helping to protect our natural resources. Did You Know: One Mary Kay ® Oil-Free Eye Makeup Remover is sold every 5 minutes around the globe. 2 Nearly 1,500 patents globally are held by Mary Kay for products, technologies, and packaging designs in its global portfolio. 3 Mary Kay's state-of-the-art Richard R. Rogers (R3) global Manufacturing/R&D Center located in Lewisville, Texas, has a production capacity of up to 1.1 million products per day. 62% of Mary Kay's global R&D teams are women. 4 81% of Mary Kay's Global Marketing team & Creative Studio are women. 5 30% of sales force members who started their Mary Kay business in the past year are under the age of 35. 6 About Mary Kay One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women's lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
